Journal Mobile Options
Table of Contents
Vol. 15, No. 2, 2002
Issue release date: March–April 2002
Skin Pharmacol Appl Skin Physiol 2002;15:100–104

Modulation of Atopy Patch Test Reactions by Topical Treatment of Human Skin with a Fatty Acid-Rich Emollient

Billmann-Eberwein C. · Rippke F. · Ruzicka T. · Krutmann J.
aClinical and Experimental Photodermatology, Department of Dermatology, University of Düsseldorf, bBeiersdorf AG, Hamburg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Measures directed at improving the skin barrier function are thought to be effective in preventing reexacerbation of atopic dermatitis, but direct proof of a prophylactic effect of emollients has been elusive. In the present study, the atopy patch test has been employed as a model for the initiation phase of atopic dermatitis in order to assess whether pretreatment of non-lesional skin with a fatty acid-rich emollient (Eucerin® Omega Creme) has a prophylactic effect in patients with atopic dermatitis. Pretreatment of test sites with Eucerin® Omega Creme either prevented or diminished the development of eczema, as compared with untreated control test sites in the same patients (n = 38). These studies indicate that the use of fatty acid-rich emollients prevents the development of atopic eczema. They also demonstrate that the atopy patch test can be used to assess the capacity of a given regimen to exert prophylactic effects in this disease.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hanifin JM: Clinical and basic aspects of atopic dermatitis. Semin Dermatol 1983:2–12.
  2. Bos JD, Wierenga EA, Smitt JHS, van der Heijden FL, Kapsenberg ML: Immune dysregulation in atopic eczema. Arch Dermatol Res 1992;128:1509–1512.
  3. Grewe M, Walther S, Gyufko K, Czech W, Schöpf E, Krutmann J: Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 1995;105:407–410.
  4. Grewe M, Bruijnzeel-Koomen CAFM, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359–361.
  5. Grewe M, Gyufko K, Schöpf E, Krutmann J: Lesional expression of interferon-gamma in atopic eczema. Lancet 1994;i:25–26.
  6. Melnik M, Plewig G: Ein neues Konzept zur Ätiopathogenese und Prävention der Atopie. Hautarzt 1989;40:685–687.

    External Resources

  7. Werner Y, Lindberg M: Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol (Stockh) 1985;65:102–105.
  8. Uehara M, Miyauchi H: The morphologic characteristics of dry skin in atopic dermatitis. Arch Dermatol 1984;120:1186–1190.
  9. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;114(suppl):146–148.
  10. Janossy M, Raguz JM, Rippke F, Schwanitz HJ: Effekte einer 12,5% Nachtkerzensamenöl-Creme auf hautphysiologische Parameter bei atopischer Diathese. H + G 1995;70:498–502.
  11. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C: House dust mite-specific T-cells in the skin of subjects with atopic dermatitis: Frequency and lymphokine profile in the allergen patch test. J Allergy Clin Immunol 1992;89:801–810.
  12. Reitamo S, Visa K, Kähönen K, Stubb S, Salo OP: Eczematous reactions in atopic patients caused by epicutaneous testing with inhalant allergens. Br J Dermatol 1986;114:275–277.
  13. Maurer D, Ebener C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G: The high affinity IgE receptor (FcεRI) mediates IgE-dependent allergen presentation. J Immunol 1996;157:607–616.
  14. Gfesser M, Rakoski J, Ring J: Vergleichende Untersuchungen zur epidermalen Barrierefunktion bei Epikutantestreaktionen und bei Atopie-Patch-Testreaktionen von Patienten mit atopischem Ekzem (abstract). Allergologie 1996;19:88–106.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50